Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
NCT ID | NCT00660621 |
Title | A Phase II Study Of Gliadel, Concomitant Temozolomide And Radiation, Followed By Dose Dense Therapy With Temozolomide Plus Bevacizumab For Newly Diagnosed Malignant High Grade Glioma |
Acronym | KARE004 |
Recruitment | Unknown status |
Gender | both |
Phase | Phase II |
Variant Requirements | No |
Sponsors | Kentuckiana Cancer Institute, Eisai Inc. |
Indications | |
Therapies | |
Age Groups: | adult | senior |
Covered Countries | USA |